Director Resignations
Released
Released
Announcement PDF
ASX Announcement
Director Resignations
28 October 2020 –Race Oncology Limited (ASX: RAC) wishes to advise that Dr Bill Garner and
Mr Chris Ntoumenopoulos have resigned from the roles of Non-Executive Director.
Non-Executive Chairman, Dr John Cullity commented, “Bill and Chris as founding directors
have been an asset to Race and we thank them both for their longstanding commitment to
the Company. We are immensely grateful of the service provided and contributions they have
made, both as Directors and shareholders, and wish them both all the best for the future.”
Dr Bill Garner commented, “Since founding Race in 2016, Chris and I have watched Race grow;
progress the strategy of bringing Bisantrene back to the clinic and now with current clinical
data and new strategic prospects, the Company is prospering. Given the time commitments
required of other ventures that we're each involved with, we are stepping out at a time when
the business is in a solid funding position and a strong state. We both wish the Company
every success.”
-
ENDS
-
About Race Oncology (RAC: ASX)
Race Oncology (RAC) is a drug development biotech with a Phase II/III cancer drug called
bisantrene. RAC has compelling clinical data for Bisantrene in acute myeloid leukaemia (AML)
as well as breast and ovarian cancer. RAC is pursuing an exciting ‘5-Path’ clinical development
strategy that involves parallel US and Australian clinical trials in AML, breast and ovarian with
clinical trials to begin in 2020.
Release authorised by:
Media contact:
Phillip Lynch, CEO & Managing Director
Jane Lowe, IR Department
phillip.lynch@raceoncology.com
+ 61 411 117 74
John Cullity, Executive Chairman
john.cullity@raceoncology.com
Race Oncology Ltd ABN 61 149 318 749
Registered office: L36, Gateway Building, 1 Macquarie Place Sydney 2000 Australia
www.raceoncology.com
Share your feedback
Discover